Diagnosis of BAC and ABAC in clinical practice-Are we doing it right?
Sarwan Bishnoi , T Iyngkaran , V Au , Amitesh Roy
Clinical Oncology Society of Australia (COSA) Conference
2009
Targeted therapy in Colorectal Cancer
Christos Karapetis , Ganessan Kichenadasse
Cancer Forum 32 ( 3) 150 -155
2008
The effect of the UGT1A1∗28 allele on survival after irinotecan-based chemotherapy: A collaborative meta-analysis
M M Dias , J-P Pignon , C S Karapetis , V Boige
Pharmacogenomics Journal 14 ( 5) 424 -431
28
2014
Germline polymorphisms as biomarkers of tumor response in colorectal cancer patients treated with anti-EGFR monoclonal antibodies: a systematic review and meta-analysis.
E K Morgen , H-J Lenz , D J Jonker , D Tu
Pharmacogenomics Journal 17 ( 6) 535 -542
1
2017
Gemcitabine and carboplatin in carcinoma of unknown primary site: a phase 2 Adelaide Cancer Trials and Education Collaborative study
K B Pittman , , I N Olver , B Koczwara
British Journal of Cancer 95 ( 10) 1309 -1313
28
2006
Do metastatic colorectal cancer patients who present with late relapse after curative surgery have a better survival
V T Broadbridge , C S Karapetis , C Beeke , R J Woodman
British Journal of Cancer 109 ( 5) 1338 -1343
16
2013
Epiregulin gene expression as a biomarker of benefit from cetuximab in the treatment of advanced colorectal cancer.
D J Jonker , C S Karapetis , C Harbison , C J O'Callaghan
British Journal of Cancer 110 ( 3) 648 -655
59
2014
The role of biological therapy in metastatic colorectal cancer after first-line treatment: a meta-analysis of randomised trials.
E Segelov , D Chan , J Shapiro , T J Price
British Journal of Cancer 111 ( 6) 1122 -1131
24
2014
Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer
A Rowland , M M Dias , M D Wiese , G Kichenadasse
British Journal of Cancer 112 ( 12) 1888 -1894
345
2015
Delayed onset of benign pleural effusion following concurrent chemoradiotherapy for inoperable non-small-cell lung cancer.
R. Kumar , G. Patel , G. Kichenadasse , S. Sukumaran
Internal Medicine Journal 45 ( 2) 218 -221
1
2015
Acute gait disturbance associated with pamidronate infusion.
C. S. KARAPETIS , D. KOTASEK , J. E. NORMAN , R. E. SAGE
Australian and New Zealand Journal of Medicine 27 ( 6) 719 -720
2
1997
Early tumor shrinkage identifies long-term disease control and survival in patients with lung cancer treated with atezolizumab.
Ashley M Hopkins , Ganessan Kichenadasse , Chris S Karapetis , Andrew Rowland
Journal for ImmunoTherapy of Cancer 8 ( 1)
6
2020
Predicting response and toxicity to immune checkpoint inhibitors using routinely available blood and clinical markers.
Ashley M Hopkins , Andrew Rowland , Ganessan Kichenadasse , Michael D Wiese
British Journal of Cancer 117 ( 7) 913 -920
86
2017
Uncertainty and the unmet informational needs of patients with cancer of unknown primary (CUP): a cross-sectional multi-site study
Lisa Guccione , Krista Fisher , Linda Mileshkin , Richard Tothill
Supportive Care in Cancer 30 ( 10) 8217 -8229
5
2022
Solving unknown primary cancer-Earlier diagnosis (SUPER-ED): A stepped wedge cluster randomised controlled trial implementing a Model of Care to support earlier diagnosis
Penelope Schofield , Anna Ugalde , Richard Tothill , Steve Quinn
2022
Phase III randomized, placebo-controlled study of cetuximab plus brivanib alaninate versus cetuximab plus placebo in patients with metastatic, chemotherapy-refractory, wild-type K-RAS colorectal carcinoma: the NCIC Clinical Trials Group and AGITG CO. 20 Trial
Lillian L Siu , Jeremy D Shapiro , Derek J Jonker , Chris S Karapetis
J Clin Oncol 31 ( 19) 2477 -2484
146
2013
Personalised supportive care for patients receiving 5-fluorouracil (5-FU): analysis of multivariate SNP risk prediction for GI toxicity
Samantha K Korver , Joanne M Bowen , Imogen A Ball , Rachel J Gibson
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY 14 58 -59
2018
Interleukin-1 Beta (IL1B) Genetic Variability is Predictive of Chemotherapy-Induced Gastrointestinal Toxicity (CIGT) Risk in Patients Receiving 5-Fluorouracil
Samantha K Korver , Imogen A Ball , Rachel J Gibson , Jonathan Tuke
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY 13 124 -124
2017
The Effect of Immune Genetic Variants on Chemotherapy-Induced Gastrointestinal Toxicity (CIGT) Risk in Patients Receiving 5-Fluorouracil
Samantha K Korver , Imogen A Ball , Rachel J Gibson , Richard M Logan
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY 13 124 -124
2017
Prognostic model of survival outcomes in non-small cell lung cancer patients initiated on afatinib: pooled analysis of clinical trial data
Ashley M Hopkins , Adel Shahnam , Sasha Zhang , Chris S Karapetis
Cancer Biology & Medicine 16 ( 2) 341 -341
5
2019